Despite the continuing improvement of automated blood cell counters, confirmation by blood smear examination remains the gold standard in case of anomalies. With a constant goal of standardisation, different experts committees (e.g. the French-speaking cellular hematology group (Groupe francophone d'hématologie cellulaire, GFHC and the ISLH International society for laboratory hematology) recently published criteria for microscopic analysis of blood smears. Cornet et al. evaluated the application of those criteria and propose to suppress any review for 72 hours when a "Blast/Abn lymph" flag is triggered for a sample with no abnormal cell on the microscopic review. The aims of our study were to retrospectively evaluate whether this 72-hour rule adequately operates and whether it is possible to extend the arbitrary 72-hour timeframe to 96h and 144h. To achieve this goal, 40,688 blood samples were collected from three French-speaking hospitals. 1,548 samples presented an isolated "Blast/Abn lymph" flag. Only 221 samples presented the application of the 72-hour rule at least once for our study period. We were able to extend this rule to 144 hours for 10 samples of them. All blood smears for which the rule was applied were verified and there was no abnormal cell on smears at 72 and 144 hours. In conclusion, the 72-hour rule derived from the GFHC's criteria is secure and reduces the slide review rate and thus the production costs and the turnaround time of hemogram results. Further investigations could confirm that its extension to 144 hours is also adequate.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1684/abc.2019.1462 | DOI Listing |
Am J Emerg Med
December 2024
Cooper University Health Care, Center for Healing, Division of Addiction Medicine, Camden, NJ, United States; Cooper Medical School of Rowan University, Camden, NJ, United States; Cooper University Health Care, Department of Emergency Medicine, Division of Addiction Medicine and Medical Toxicology, Camden, NJ, United States.
J Addict Med
June 2024
From the Department of Adult Medicine, East Boston Neighborhood Health Center, Boston, MA (MS); Internal Medicine Residency Program, Boston Medical Center, Boston, MA (SS); Division of General Internal Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO (PJC); Section of General Internal Medicine, Boston University Chobanian and Avedisian School of Medicine & Boston Medical Center, Boston, MA (JL, GKK, JLT, HR); Grayken Center for Addiction, Boston Medical Center, Boston, MA (JL, GKK, JLT, HR); The Dimock Center, Boston, MA (JE); Department of Pharmacy, Boston Medical Center, Boston, MA (NMF); and Department of Emergency Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, MA (NMF).
Background: Federal regulations restrict methadone for opioid use disorder (OUD) treatment to licensed opioid treatment programs (OTPs). However, providers in other settings can administer methadone for opioid withdrawal under the "72-hour rule" while linking to further care. Prior work has demonstrated that methadone initiation in a low-barrier bridge clinic is associated with high OTP linkage and 1-month retention rates.
View Article and Find Full Text PDFJ Addict Med
February 2024
From the Department of Pharmacy, Oregon Health & Science University, Portland, OR (ES, JS); and Section of Addiction Medicine, Department of Medicine, Oregon Health & Science University, Portland, OR (HE).
Objectives: Methadone for opioid use disorder treatment in ambulatory settings is restricted to federally licensed opioid treatment programs (OTPs) in the United States. However, these restrictions do not apply during hospitalization. A recent change to the rule governing methadone in non-OTP settings created an opportunity to dispense methadone at hospital discharge for up to 72 hours.
View Article and Find Full Text PDFJ Emerg Med
March 2023
Cooper University Health Care, Center for Healing, Division of Addiction Medicine, Camden, New Jersey; Cooper Medical School of Rowan University, Camden, New Jersey; Department of Emergency Medicine, Division of Addiction Medicine and Medical Toxicology.
Background: In an era of fentanyl and continually rising rates of opioid overdose deaths, increasing access to evidence-based treatment for opioid use disorder (OUD) should be prioritized. Emergency department (ED) buprenorphine initiation for patients with OUD is considered best-practice. Methadone, though also evidence-based and effective, is under-utilized due to strict federal regulation, significant stigma, and lack of physician training.
View Article and Find Full Text PDFDrug Alcohol Depend
July 2022
Grayken Center for Addiction, Boston Medical Center, Boston, MA, USA; Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA.
Background: Methadone for opioid use disorder (OUD) treatment is restricted to licensed opioid treatment programs (OTPs) with substantial barriers to entry. Underutilized regulations allow non-OTP providers to administer methadone for opioid withdrawal for up to 72 h while arranging ongoing care. Our low-barrier bridge clinic implemented a new pathway to treat opioid withdrawal and facilitate OTP linkage utilizing the "72-hour rule.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!